In Brief: Knoll Pharmaceuticals
Knoll Pharmaceuticals: Former Boots Pharmaceuticals, Inc. CEO Carter Eckert to Knoll Pharmaceuticals president and group VP of BASF Corp. Lincolnshire, Ill.-based Boots Pharmaceuticals, the worldwide ethical pharmaceutical arm of The Boots Company, was merged into Mount Olive, N.J.-based Knoll following its acquisition by BASF on April 1...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth